年轻隐源性卒中患者系统遗传学评估:ES-EASY项目
该研究对50岁以下卒中患者进行回顾性观察联合前瞻性基因检测,发现系统遗传学分析在隐源性卒中年轻患者中诊断率为20.3%,单基因病因占全部年轻卒中3.9%,且多数确诊患者无卒中家族史。
要点
- 年轻隐源性卒中患者应考虑系统遗传学检测,即使无家族史。
- 遗传性心脏病和心血管风险相关疾病占诊断的50%。
- 单基因病因解释了3.9%的年轻卒中病例。
核心结论
- 对所有不明原因卒中或已知单基因形式的卒中亚型应考虑遗传学分析,即使没有提示性家族史。
研究设计与样本
- 回顾性观察队列研究联合前瞻性基因检测,筛查2018至2021年Dijon大学医院卒中单元收治的50岁以下卒中患者305例。
主要发现
- 队列1中24例既往基因检测,8例(33%)获得分子诊断。
- 队列2中35例接受外显子测序,4例(11%)发现致病性变异。
- 两队列合计基因检测诊断率为20.3%(12/59)。
- 单基因病因占全部年轻卒中病例的3.9%(12/305)。
- 66%的确诊患者无卒中家族史,遗传性心脏病和心血管风险相关疾病占诊断的50%。
临床怎么用
- 对年轻隐源性卒中患者,即使无家族史,也应考虑系统遗传学检测。
- 对已知单基因形式的卒中亚型(如烟雾病综合征、心脏病、小血管病)应进行遗传学分析。
局限性
- 回顾性观察设计,部分患者为前瞻性基因检测。
- 队列2仅35例同意基因检测,可能存在选择偏倚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Up to 15% of strokes occur in young adults, with more cryptogenic cases, raising the possibility of rare causes, such as genetic diseases. Although available in everyday practice, genetic analyses are usually reserved for patients with evocative personal or family history. We aimed to assess the interest of systematic genetic analyses in young adults with cryptogenic stroke and estimate the true frequency of genetic disorders in such patients. METHODS: We conducted a retrospective observational cohort study with additional prospective genetic testing. We screened all patients under 50 admitted to Dijon University Hospital stroke unit between 2018 and 2021. Those already genetically tested during etiological work-up were included in a first cohort (cohort 1). Among the remaining patients, those with unexplained intracerebral hemorrhage or stroke (ie, cryptogenic stroke), or a stroke subtype known to have monogenic forms, were offered exome sequencing to form cohort 2. Monogenic diagnoses were defined by likely pathogenic/pathogenic variants according to American College of Medical Genetics and Genomics criteria. RESULTS: Among 305 patients with stroke screened, 24 had prior genetic testing (cohort 1) with exome sequencing, genome sequencing, gene panels or targeted gene analyses, leading to a molecular diagnosis in 8 (33%). Of the remaining 281 patients, 71 met eligibility criteria and 35 consented to the study (cohort 2). Exome sequencing identified pathogenic variants in 4 of them (11%). The overall diagnostic yield of genetic tests was 20.3% (12/59 patients tested across both cohorts). In total, monogenic causes explained 3.9% (12/305) of all young stroke cases. Notably, most diagnosed patients (66%) had no family history of stroke. Genetic cardiopathies and conditions conferring increased cardiovascular risk factors accounted for 50% of diagnoses. CONCLUSIONS: Genetic analyses should be considered in all unexplained strokes or in stroke subtypes with known genetic forms (eg, moyamoya syndrome, cardiopathy, small vessel disease), even without an evocative family history.
引用
- Mania-Pâris L, Vitobello A, Safraou H, et al. Systematic Genetic Assessment in Young Patients With Cryptogenic Stroke: The ES-EASY project. Stroke. 2025. PMID: 40970272. doi:10.1161/STROKEAHA.125.051020
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。